Joe Catanese, CEO
Jee Shin, Founder & CBO
Calyxo is a commercial stage medical device company that has developed a disruptive technology for minimally invasive kidney stone removal.
“If you focus on the patient, the rest will follow. Questa gets that and it is very empowering and liberating.”
Joe Catanese
President & CEO
Their story
Kidney stone disease affects millions of patients each year, yet traditional treatment methods often present challenges for both physicians and patients. Existing stone management techniques can be complex, inefficient, and prone to complications, leading to inconsistent outcomes.
Calyxo was founded by a team of medtech professionals to address these limitations and advance kidney stone treatment with innovative technology. By developing solutions that enhance procedural efficiency and effectiveness, Calyxo is helping urologists provide better care while improving the patient experience.
Committed to evidence-based innovation and physician collaboration, Calyxo continues to refine its technology to meet the evolving needs of kidney stone treatment. The company's goal is to reduce procedural complexity, minimize complications, and improve overall outcomes.
.avif)
Our partnership
Our relationship with Calyxo began long before our investment, having known founder Jee Shin for nearly 20 years. We have tracked the company’s progress from inception given our relationship with Jee and our strong interest and expertise in the urology market.
Recognizing the product’s potential and the immense market opportunity, we identified the chance to strengthen Calyxo’s team by recruiting former NeoTract executives — leaders we had previously backed in building a successful urology company. Since our investment, Calyxo has secured FDA clearance and successfully launched its CVAC system, achieving strong commercial growth.
The team involved
.avif)